A Phase 1 interventional study of Tisagenlecleucel and Ibrutinib in Diffuse Large B-cell Lymphoma, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-31.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 10 under way, 2 of them phase 3. ibrutinib · Lymphoma, Large B-Cell, Diffuse.
Among the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 25th largest by enrollment, is one of 4 that started in 2019, is one of 9 in phase 1, and was the 19th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →3 of the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Yazeed Sawalha · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 14 · Phase 3 3
First in 2011; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 44 across the 26 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
31 studies in Lymphoma, Large B-Cell, Diffuse by Novartis: 4 open now, 5 under way, 1 of them phase 3. Of 24 finished, 8 (33%) have results posted.
Among the 31 studies in Lymphoma, Large B-Cell, Diffuse by Novartis, this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is one of 8 that started in 2019, is one of 8 in phase 1, and was the 13th registered.
Novartis’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 1998.
5 of the studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
| NCT06536049Yazeed SawalhaEpcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Novartis’s 31 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
A multi-center, open-label, phase Ib study to evaluate the safety and tolerability of the administration of tisagenlecleucel in combination with ibrutinib in patients with r/r DLBCL who have received two or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy, and who have progressed after or are not candidates for ASCT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other eligibility criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will start ibrutinib treatment before leukapheresis
Biological: Tisagenlecleucel · Drug: Ibrutinib
Patients will start ibrutinib treatment after leukapheresis.
Biological: Tisagenlecleucel · Drug: Ibrutinib
Infusion
Oral (tablets or capsules)
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Month 24 is planned study end
Time frame: 24 months
Severity of adverse events (AEs) and serious adverse events (SAEs)
Month 24 is planned study end
Time frame: 24 months
Ibrutinib dose modification following tisagenlecleucel infusion
Month 24 is planned study end
Time frame: 24 months
Response Rate
3-months post tisagenlecleucel infusion, assessed by local investigator according to Lugano criteria
Time frame: Month 3
Response Rate
6-month post tisagenlecleucel infusion, assessed by local investigator according to Lugano criteria
Time frame: Month 6
Overall Response Rate
Time frame: 24 months
Duration of Response
Time frame: 24 months
Progression Free Survival (PFS)
Time frame: 24 months
Overall Survival (OS)
Time frame: 24 months
Tisagenlecleucel transgene concentrations
qPCR will be used to measure tisagenlecleucel transgene concentrations in available tissue, such as peripheral blood, bone marrow, tumor/lymph node tissue, and/or CSF.
Time frame: 24 months
Cellular kinetics of Tisagenlecleucel (Cmax)
Cmax cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib
Time frame: 24 months
Cellular kinetics of Tisagenlecleucel (Tmax)
Tmax cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib
Time frame: 24 months
Cellular kinetics of Tisagenlecleucel (AUC)
AUC cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib
Time frame: 24 months
Cellular kinetics of Tisagenlecleucel (Clast)
Clast cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib
Time frame: 24 month
Cellular kinetics of Tisagenlecleucel (Tlast)
Tlast cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib
Time frame: 24 month
Anti-drug antibody (ADA) response to Tisagenlecleucel (humoral immunogenicity)
Pre-existing and treatment related immunogenicity (humoral) of tisagenlecleucel will be characterized by flow cytometry
Time frame: 24 months
Anti- tisagenlecleucel t-cell response (cellular immunogenicity)
Pre-existing and treatment related immunogenicity (cellular) of tisagenlecleucel will be characterized IFN-g staining and flow cytometry
Time frame: 24 months
Characterize cellular kinetic parameters in the presence of ADA and/or anti-tisagenlecleucel t-cell response
Time frame: 24 months
Characterize efficacy of tisagenlecleucel in the presence of ADA and/or anti-tisagenlecleucel t-cell response
Time frame: 24 month
Ran from Jun 2019 to primary completion in Nov 2021, 28 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tisagenlecleucel · Ibrutinib
Lymphoma, Large B-Cell, Diffuse →